Multimodal evaluation of in vivo magnetic resonance imaging of myocardial restoration by mouse embryonic stem cells  by Hendry, Stephen L. et al.
CSPMultimodal evaluation of in vivo magnetic resonance
imaging of myocardial restoration by mouse embryonic
stem cells
Stephen L. Hendry, II, MD,a* Koen E. A. van der Bogt, MS,a,e* Ahmad Y. Sheikh, MD,a Takayasu Arai, MD,b
Scott J. Dylla, PhD,c Micha Drukker, PhD,c Michael V. McConnell, MD,b Ingo Kutschka, MD,a Grant Hoyt, BS,a
Feng Cao, MD, PhD,d Irving L. Weissman, MD,c Andrew J. Connolly, MD, PhD,c Marc P. Pelletier, MD,a
Joseph C. Wu, MD, PhD,b,d Robert C. Robbins, MD,a and Phillip C. Yang, MDb
Supplemental material is
available online.
Objective: Mouse embryonic stem cells have demonstrated potential to restore in-
farcted myocardium after acute myocardial infarction. Although the underlying mech-
anism remains controversial, magnetic resonance imaging has provided reliable in
vivo assessment of functional recovery after cellular transplants. Multimodal compar-
ison of the restorative effects of mouse embryonic stem cells and mouse embryonic
fibroblasts was performed to validate magnetic resonance imaging data and provide
mechanistic insight.
Methods: SCID-beige mice (n5 55) underwent coronary artery ligation followed by
injection of 2.5 3 105 mouse embryonic stem cells, 2.5 3 105 mouse embryonic
fibroblasts, or normal saline solution. In vivo magnetic resonance imaging of myocar-
dial restoration by mouse embryonic stem cells was evaluated by (1) in vivo pressure–
volume loops, (2) in vivo bioluminescence imaging, and (3) ex vivo TaqMan (Roche
Molecular Diagnostics, Pleasanton, Calif) polymerase chain reaction and immunohis-
tologic examination.
Results: In vivo magnetic resonance imaging demonstrated significant improvement
in left ventricular ejection fraction at 1 week in the mouse embryonic stem cell group.
This finding was validated with (1) pressure–volume loop analysis demonstrating
significantly improved systolic and diastolic functions, (2) bioluminescence imaging
and polymerase chain reaction showing superior posttransplant survival of mouse
embryonic stem cells, (3) immunohistologic identification of cardiac phenotypewithin
engrafted mouse embryonic stem cells, and (4) polymerase chain reaction measuring
increased expressions of angiogenic and antiapoptotic genes and decreased expres-
sions of antifibrotic genes.
Conclusion: This study validates in vivo magnetic resonance imaging as an effective
means of evaluating the restorative potential of mouse embryonic stem cells.
C
ellular therapy is rapidly emerging as a potential therapeutic option after acute
myocardial infarction (AMI).1 Although studies have shown that transplants
of stem cells derived from different lineages can provide significant functional
recovery in the setting of AMI, the exact mechanisms of cell-mediated restoration
have not been established.2 There are several theories regarding the possible
From the Department of Cardiothoracic Sur-
gery,a the Division of Cardiovascular Medi-
cine,b and the Department of Pathology,c
Stanford University School of Medicine,
and the Molecular Imaging Program at Stan-
ford (MIPS),d Stanford University, Stanford,
Calif; and the Department of Surgery, Lei-
den University Medical Center, Leiden,
The Netherlands.e
Supported by the NRSA Fellowship
HL082447-01 (S.L.H.), Donald W. Rey-
nolds Foundation (P.C.Y.), Falk Cardiovas-
cular Research Fund (R.C.R.), and National
Institutes of Health grants F32 and K23
HL04338-01 (P.C.Y.).
*Both authors contributed equally to this
study.
Received for publication Sept 4, 2007;
revisions received Dec 5, 2007; accepted
for publication Dec 18, 2007.
Address for reprints: Phillip C. Yang, MD,
Department of Cardiovascular Medicine,
Falk Cardiovascular Research Center, Stan-
ford University Medical Center, 300 Pasteur
Dr, Stanford, CA 94305 (E-mail: pyang@
cvmed.stanford.edu).
J Thorac Cardiovasc Surg 2008;136:1028-
37
0022-5223/$34.00
Copyright  2008 by The American Asso-




Physiology1028 The Journal of Thoracic and Cardiovascular Surgery c October 2008
Hendry II et al Cardiopulmonary Support and Physiology
CS
PAbbreviations and Acronyms
AMI 5 acute myocardial infarction
BLI 5 bioluminescence imaging
Ees 5 end-systolic elastance
EMax 5 maximal elastance
fluc 5 firefly luciferase gene
GFP 5 green fluorescent protein
LAD 5 left anterior descending coronary artery
LVEF 5 left ventricular ejection fraction
mEF 5 mouse embryonic fibroblast
mESC 5 mouse embryonic stem cell
MMP 5 matrix metalloproteinase
MRI 5 magnetic resonance imaging
NS 5 normal saline solution treatment
POD 5 postoperative day
PV 5 pressure–volume
RT-PCR 5 reverse transcriptase polymerase chain reaction
TM-PCR 5 TaqMan polymerase chain reaction
TNF a 5 tumor necrosis factor a
VEGF 5 vascular endothelial growth factor
mechanisms underlying myocardial restoration after cellular
therapy: (1) augmentation of the infarct region’s elasticity,
preserving regional systolic and diastolic functions; (2) con-
tractility of engrafted cells, improving systolic function; (3)
angiogenesis, enhancing regional myocardial perfusion;
and (4) paracrine effects, modulating the progression of car-
diac remodeling.3-6
In vivo magnetic resonance imaging (MRI) has demon-
strated improved cardiac function after stem cell transplants
in both preclinical and clinical investigations.1,7-11 These find-
ings have led to questions regarding the validity of such data,
and more importantly regarding the potential mechanisms un-
derlying myocardial restoration. This investigation addresses
these issues by validating in vivo MRI evaluation of myocar-
dial restoration through a systematic comparison of the restor-
ative potential of ‘‘nonspecific’’ mouse embryonic fibroblasts
(mEFs) with the more biologically active, self-renewing, plu-
ripotent mouse embryonic stem cells (mESCs) in a murine
model of AMI. This is the first study to validate in vivo MRI
at a functional level and to conduct a multimodal evaluation




Undifferentiated D3-derived mESCs (American Type Culture Col-
lection, Manassas, Va) were cultured in Dulbecco modified Eagle
medium (Invitrogen Corporation, Carlsbad, Calif) with 15% fetal
calf serum (HyClone Laboratories Inc, Logan, Utah), 100-mg/mL
penicillin–streptomycin, 1-mmol/L sodium pyruvate, 2-mmol/L
L-glutamine, 0.1-mmol/L nonessential amino acids, 0.1-mmol/L
b-mercaptoethanol (Invitrogen), and 106-m/mL leukemia inhibitoryThe Journal of Thorfactor (Chemicon International, Inc, Temecula, Calif). Fresh mEFs
were prepared from 13-day embryos, which were minced and passed
10 times through a 21-gauge needle. Cells were seeded in 10-cm cul-
ture dishes and were propagated for two passages in Dulbecco mod-
ified Eagle medium with 10% fetal calf serum and 100-mg/mL
penicillin–streptomycin solution. Both mESCs and mEFs were
transfected with a lentiviral vector carrying a cytomegalovirus pro-
moter driving both a firefly luciferase (fluc) reporter gene and the
gene for green fluorescent protein (GFP). Cells underwent fluores-
cence-activated cell sorting for GFP and single clone selection; the
clone was adapted to feeder-free conditions. Before injection, the
cells were trypsinized (0.25% trypsin/0.02% ethylenediaminetetra-
acetic acid) and washed with Dulbeccomodified Eagle medium con-
taining 10% serum. After centrifugation, the cells were washed with
phosphate-buffered saline solution, centrifuged, and resuspended in
phosphate-buffered saline solution for injection 1 hour after trypsini-
zation.
Experimental Animals
Animal care and interventions were provided in accordance with the
Laboratory Animal Welfare Act, and all animals received humane
care and treatment in accordance with the ‘‘Guide for the Care and
Use of Laboratory Animals’’ (www.nap.edu/catalog/5140.html).
Immunotolerant SCID-beige female mice (8–12 weeks old; Charles
River Laboratories, Inc, Wilmington, Mass) were anesthetized in an
isoflurane inhalational chamber and endotracheally intubated with
a 20-gauge angiocatheter (Ethicon Endo-Surgery, Inc, Cincinnati,
Ohio). Ventilation was maintained with a Harvard rodent ventilator
(Harvard Apparatus, Inc, Holliston,Mass). AMIwas created by liga-
tion of the mid left anterior descending coronary artery (LAD)
through a left thoracotomy. The mice were randomly allocated to
three groups: (1) LAD ligation with normal saline solution injection
(NS group, n5 10), (2) LAD ligation with mESC injection (mESC
group, n 5 25), and (3) LAD ligation with mEF injection (mEF
group, n 5 20). The infarct region was injected with a Hamilton
syringe containing a 25-mL volume of 250,000 mESCs, 250,000
mEFs, or normal saline solution. Cell suspensions contained rhoda-
mine beads (63 105) to ensure injection accuracy. After chest tube
placement, the chest was closed in two layers with 5-0 Vicryl suture
(Ethicon, Inc, Somerville, NJ).
In Vivo MRI
One week after transplant, cardiac MRI was performed with a Unity
Inova console (Varian, Inc, Palo Alto, Calif) controlling a 4.7-T,
15-cm horizontal-bore magnet (Oxford Instruments, Ltd, Oxford,
UK) with GE Techron Gradients (12 G/cm; GE Medical Systems,
Milwaukee, Wis) and a volume coil with a diameter of 3.5 cm
(Varian). The electrocardiographic gating was optimized with two
subcutaneous precordial leads with respiratory motion and body
temperature monitors (SA Instruments, Inc, Stony Brook, NY).
Left ventricular function was evaluated with electrocardiographi-
cally triggered cine sequence (echo-time 2.8 ms, repetition time
160ms, flip angle 60, field of view 3.0 cm2, matrix 1283 128, slice
gap 0 mm, slice thickness 1.0 mm, number of excitations 8, and 12
cardiac phases). The imaging plane was localized with double-obli-
que acquisition. The data were analyzed with MRVision software
(MRVision Co,Winchester,Mass). Left ventricular ejection fraction
(LVEF) and left ventricular end-diastolic and end-systolic volumesacic and Cardiovascular Surgery c Volume 136, Number 4 1029
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CSPwere calculated by tracing the endocardial borders in end-systole and
end-diastole.
Pressure–Volume Loop Analysis
One week after transplant, ventricular performance was assessed by
pressure–volume (PV) loopanalysiswith a 1.4Fconductance catheter
(Millar Instruments, Inc, Houston, Tex) before the animals were sac-
rificed. The closed-chest technique was used; this consisted of a mid-
line neck incision to access the left external jugular vein with PE10
tubing (Intramedic; BD Diagnostic Systems, Sparks, Md). The right
carotid artery was cannulated with theMillar catheter, which was ad-
vanced through the aortic valve into the left ventricle. The PV
relationsweremeasured at baseline and during inferior vena caval oc-
clusion. Themeasurements of segmental conductancewere recorded,
which allowed extrapolation of the left ventricular volume. When
coupled with pressure, the generation of ventricular PV relationships
allowed precise hemodynamic characterization of ventricular systolic
and diastolic function and loading conditions.12 These data were an-
alyzed with PVAN 3.4 Software (Millar) and Chart/Scope software
(ADInstruments, Inc, Colorado Springs, Colo).
In Vitro fluc expression Assay
On the day of operation, parallel sets of cells from the same plates as
the injected cells were trypsinized, resuspended in phosphate-buff-
ered saline solution, and divided into a 6-well plate in different con-
centrations. After administration of D-luciferin (4.5 mg/mL; Caliper
Life Sciences/Xenogen, Alameda, Calif), peak signal expressed as
photons per second per square centimeter per steridian was mea-
sured with a charge-coupled device camera (Xenogen).
In Vivo Optical Bioluminescence Imaging
Optical bioluminescence imaging (BLI) was performed with 83 5-
minute acquisition scans on a charge-coupled device camera (IVIS
50; Xenogen). Recipient mice were anesthetized and placed in the
imaging chamber. After acquisition of a baseline image, mice
were intraperitoneally injected with D-luciferin (400 mg/kg body
weight; Xenogen). Peak signal from a fixed region of interest was
evaluated with Living Image 2.50 software (Xenogen).
Ex Vivo TaqMan Polymerase Chain Reaction for Cell
Survival and Expressions of Genes of Interest
Because the transplanted cells were derived from male mice and
were transplanted into female recipients, the surviving mESCs in
the explanted hearts could be quantified by using TaqMan (Roche
Molecular Diagnostics, Pleasanton, Calif) polymerase chain reac-
tion (TM-PCR) to track the Sry locus found on the Y chromosome.
Whole explanted hearts were minced and homogenized in DNAzol
(Invitrogen). RNA was extracted from the myocardium after treat-
ment with TRIzol reagent (Invitrogen). TM-PCR was performed
with the SuperScript II reverse transcriptase PCR (RT-PCR) kit (In-
vitrogen). To assess the expressions of several genes of interest,
relative quantitation of mouse primers was performed for the follow-
ing: matrix metalloproteinases (MMPs) 1b, 2, 9, and 14; tumor
necrosis factor a (TNF-a), vascular endothelial growth factor A
(VEGF-A), procollagen 2a1, transforming growth factor b, angio-
tensin-converting enzyme, insulinlike growth factor 1, kinase insert
domain protein receptor, and nuclear factor kB-1 (Applied Biosys-
tems, Foster City, Calif). The fluorogenic probes contained1030 The Journal of Thoracic and Cardiovascular Surgery c Oca 50-FAM report dye and 30-BHQ1 quencher dye. TaqMan 18S Ri-
bosomal RNA (Applied Biosystems) was used as a control gene.
RT-PCR reactions were conducted in iCycler IQ Real-Time Detec-
tion Systems (Bio-Rad Laboratories Inc, Hercules, Calif).
Histologic Analysis
Hearts were flushed with normal saline solution and subsequently
placed in 2% paraformaldehyde for 2 hours at room temperature,
followed by 12 to 24 hours in 30% sucrose at 4C. The tissue was
embedded in Optical Cutting Temperature Compound (Tissue-
Tek; Sakura Finetek USA Inc, Torrance, Calif) and snap frozen
on dry ice. Sections of 5 mmwere cut in both the proximal and apical
regions of the infarct zone. Slides were stained with hematoxylin
and eosin, anti-GFP (anti–green fluorescent protein, rabbit IgG frac-
tion, anti-GFP Alexa Fluor 488 conjugate, 1:200; Molecular Probes,
Inc, Eugene, Ore), anti–troponin I (H-170 rabbit polyclonal IgG for
cardiac muscle, 1:100; Santa Cruz Biotechnology, Inc, Santa Cruz,
Calif), and anti–connexin 43 (rabbit polyclonal, 1:100; Sigma, St
Louis, Mo). Stained tissue was examined with a Leica DMRB fluo-
rescent microscope (Leica Microsystems Inc, Deerfield, Ill) and
a Zeiss LSM 510 2-photon confocal laser scanning microscope
(Carl Zeiss, Inc, Thornwood, NY). Cell engraftment was confirmed
by identification of GFP expression under fluorescent microscopy.
Colocalization of troponin, a-sarcomeric actin, and connexin 43
with GFP was visualized with streptavidin conjugated with Alexa
Fluor Red 555 (Invitrogen).
Statistical Analysis
Descriptive statistics included mean and SE. Comparison between
groups was performed with the Student t test for independent and
normally distributed data variables with SPSS 11.0 (SPSS Inc, Chi-
cago, Ill). For comparisons between multiple groups, analysis of
variance with Bonferroni correction was used.
Results
Quantitation of LVEF by in Vivo MRI
As seen in Figure 1 (A and B), MRI indicated that AMI led to
significant reduction in LVEF at 1 week in all groups relative
to sham-operated, normal hearts (60.9%6 1.4%, n5 5, P,
.01), illustrating the effectiveness of this murine AMI model.
In the mESC group, a significant improvement of LVEF
(40.2% 6 2.0%, n 5 23) was seen relative to both mEF
(29.4% 6 1.5%, n 5 17) and NS (26.4% 6 1.8%, n 5 6,
P , .05) groups. No significant improvement was observed
in the mEF group relative to the NS group. Measurements of
left ventricular end-diastolic and end–systolic volumes are
included in Table E1.
Measurement of Maximal Elastance and End-Systolic
Elastance by PV Loop Analysis
As seen in Figure 1,C, PV loop analysis demonstrated signif-
icantly compromised maximal elastance (Emax) in the mEF
group (9.95 6 1.4 mm Hg/mL, n 5 4) and the NS group
(5.86 1.2 mmHg/mL, n5 4) relative to that in normal hearts
(22.66 2.5 mmHg/mL, n5 5, P, .05) at 1 week; however,
Emax was noticeably preserved in the mESC group (18.4 6tober 2008
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PFigure 1. Functional outcomes after mouse embryonic stem cell and mouse embryonic fibroblast transplants. A,
Representative magnetic resonance images for each group (normal, mouse embryonic stem cell [mESC], mouse em-
bryonic fibroblast [mEF], and normal saline–treated [NS]) shown in end-diastole and end-systole at 1 week after left
anterior descending coronary artery ligation and cellular transplant. Mouse embryonic stem cell group demon-
strated increased left ventricular ejection fraction, with visual confirmation from magnetic resonance images. B,
One week after left anterior descending coronary artery ligation and cellular transplant, magnetic resonance imag-
ing indicated significant improvement in left ventricular ejection fraction (LVEF) in mouse embryonic stem cell
(mESC) group versus mouse embryonic fibroblast (mEF) and normal saline–treated (NS) groups. Asterisk represents
P< .05 versus mouse embryonic fibroblast and normal saline–treated groups by analysis of variance. Double aster-
isk indicates P< .01 versus all groups by analysis of variance. C, One week after left anterior descending coronary
artery ligation and cellular transplant, PV loop analysis demonstrated compromised maximum elastance (Emax) in
mouse embryonic fibroblast (mEF) and normal saline–treated (NS) groups relative to normal hearts. Preserved max-
imum elastance was noticeable in mouse embryonic stem cell (mESC) group, with significantly higher value than in
normal–saline treated group. No significant improvement was observed in maximal elastance in mouse embryonic
fibroblast group relative to normal saline–treated group. End-systolic elastance (Ees) data show significant de-
crease in normal saline–treated (NS) group relative to normal hearts and significant preservation of end-systolic
elastance in mouse embryonic stem cell (mESC) group relative to normal saline–treated group. No significant im-
provement was observed in mouse embryonic fibroblast (mEF) group relative to normal saline–treated group. Aster-
isk indicates p< .05 versus mouse embryonic fibroblast and normal saline–treated groups. Dagger indicates P< .05
versus normal saline–treated group (n> 4/ group by analysis of variance). D, Pressure–volume loop measurements
of left ventricular volumes (V) in end-systole (Ves) and end-diastole (Ved) show nonsignificantly decreased ventric-
ular dilatation in mouse embryonic stem cell (mESC) group relative to other treatment groups.mEF,mouse embryonic
fibroblast; NS, normal saline treatment. E, Scatter plot of average left ventricular volumes in each group measured
by pressure–volume loop (V-PV) and magnetic resonance imaging (V-MRI), with r2 5 0.76.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 1031
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CSP3.5 mm Hg/mL, n 5 4) and significantly higher than that in
the mEF and NS groups (P , .05). No significant improve-
ment was observed in Emax in the mEF group relative to
theNS group. The end-systolic elastance (Ees) data paralleled
these findings, with a significant decrease in theNS group (4.1
6 0.7 mm Hg/mL, n 5 4) relative to normal hearts (12.5 6
1.2mmHg/mL, n5 5,P, .05) and a significant preservation
of Ees in the mESC group (8.86 1.5 mm Hg/mL, n5 4) rel-
ative to the mEF and NS groups (P, .05). No significant im-
provement in Ees was observed in the mEF group relative to
the NS group. As shown in Figure 1, D, the left ventricular
volumes measured by PV loop analysis in the mEF and NS
groups demonstrated negative remodeling, whereas hearts
in the mESC group showed the least dilatation. The improved
systolic and diastolic functionsmeasured by the PV loops pro-
vide physiologic confirmation of in vivo MRI data, with cor-
relation of left ventricular volumes measured byMRI and PV
loop (Figure 1,E). Table E1 lists further results of invasive he-
modynamic measurements.
Determination of Transplanted Cell Survival by
in Vivo BLI and ex Vivo TM-PCR
Stable mESC and mEF transfection with GFP and fluc gen-
erated mESC-GFP1-fluc1 and mEF-GFP1-fluc1 cell lines.
The cells were selected and tested for fluc signal by BLI. For
both lines, expression of fluc signal correlated robustly with
cell number (r25 0.99 and r25 0.95, respectively, Figure 2,
A–C). BLI was thus validated as a tool for monitoring cell
viability quantitatively, with the signal intensity reflecting
the number of viable cells in vitro. After transplant of the
transfected cells, BLI signal from the mESC group de-
creased until postoperative day (POD) 2. At PODs 8 and
14, there was a significant (P , .01) increase in signal as
a result of the rapid division of the undifferentiated mESCs
(Figure 3, A and B), probably commencing teratoma forma-
tion as already shown in our earlier work.13 In the mEF
group, however, signal increased until POD 2 but decreased
thereafter, suggesting cell death (Figure 3, A and B). Ex vivo
TM-PCR results indicated significantly lower cycle numbers
with time in the mESC group relative to the increasing cycle
numbers in the mEF group (Figure 3, C), which is represen-
tative of higher number of viable male donor cells in the
mESC group.14 Ex vivo TM-PCR thus correlated well
with the BLI results (Figure 3, D). This finding supports
in vivo MRI data in which cell survival, a major biologic
property, is significantly enhanced for the transplanted
mESCs to remain biologically active to restore the injured
myocardium.
Figure 2. In vitro firefly luciferase signal corre-
lates with cell number. A and B, Bioluminescence
images show increasing signal with increasing
cell number in mouse embryonic stem cells (A)
and mouse embryonic fibroblasts (B). Bars repre-
sent maximum radiance. C, Correlation plot
shows robust correlation between signal and
cell number for mouse embryonic stem cells
(mESC, (r2 5 0.99) and mouse embryonic fibro-
blasts (mEF, r2 5 0.95).1032 The Journal of Thoracic and Cardiovascular Surgery c October 2008
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PFigure 3. Transplanted cell survival by in vivo bioluminescence and ex vivo TaqMan polymerase chain reaction. A,
Representative bioluminescence images of mouse embryonic stem cell (mESC) and mouse embryonic fibroblast
(mEF) survivals, tracked longitudinally at postoperative days (POD) 0, 2, 8, and 14. Mouse embryonic stem cell sur-
vival decreased from postoperative day 0 to postoperative day 2, after which there were notable increases at post-
operative days 8 and 14 from rapid division. Color bars represent maximum radiance. B, Normalized plot indicating
significant (P< .01) mouse embryonic stem cell (mESC) proliferation starting on postoperative day (POD) 2 and grad-
ual cell death in mouse embryonic fibroblast (mEF) group starting on postoperative day 2 (n > 4/group). Ordinate
shows log10 percentage of average bioluminescence signal on postoperative day 0. Asterisk indicates P < .01 by
analysis of variance versus mouse embryonic stem cells on postoperative days 0 and 2 and versus mouse embryonic
fibroblasts for all time points. C, Ex vivo TaqMan polymerase chain reaction for Sry gene representing male mouse
embryonic stem cell (mESC) survivals at postoperative days (PODs) 0, 2, 8, and 14, demonstrating similar trend to that
of in vivo bioluminescence imaging (n> 4/group). Asterisk indicates P< .05 versus mouse embryonic fibroblasts by
analysis of variance. Double asterisk indicates P < .01 versus mouse embryonic fibroblasts (mEF) by analysis of
variance. D, Correlation plot showing correlations (r2 5 0.86 and r2 5 0.87 for mouse embryonic stem cell (mESC)
and mouse embryonic fibroblast (mEF) groups, respectively) between in vivo bioluminescence imaging and
ex vivo TaqMan polymerase chain reaction.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 1033
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CSPGene expression profiling by TM-PCR for MMP-1b,
MMP-2, MMP-9, MMP-14, TNF-a, VEGF-A,
procollagen 2a1, insulinlike growth factor 1,
transforming growth factor-b, angiotensin-converting
enzyme, kinase insert domain protein receptor, and
nuclear factor kB-1
Relative quantitation of messenger RNA expression of 12
genes (4 mice/group) with RT-PCR demonstrated significant
increase of TNF-a in the mESC group relative to the mEF and
NS groups (501% vs 77% and 219%, respectively, P, .01).
Significant upregulation of VEGF-Awas also observed in the
mESC group relative to the mEF and NS groups (104% vs
13% and 42%, respectively, P , .01). On the other hand,
mESC-treated mice demonstrated a trend toward downregu-
lation of MMP-1b and procollagen 2a1 expressions relative
to the NS group (P. .05). The messenger RNA expressions
of the remainder of genes (for insulinlike growth factor 1,
nuclear factor kB-1, MMP-2, MMP-9, MMP-14, transform-
ing growth factor b, angiotensin-converting enzyme, and
kinase insert domain protein receptor) did not demonstrate
significant difference among mESC, mEF, and NS groups.
The gene expression profiles of TNF-a, which may have
had an enhanced antiapoptotic effect, and VEGF-A, consis-
tent with proangiogenic effects, were demonstrated in the
mESC group (Figure 4).
Immunohistologic Evidence of mESC Cardiomyocyte
Differentiation
As seen in Figure 5 (A–D), cross-sectional images of hema-
toxylin and eosin–stained hearts demonstrated thinning of
myocardial tissue and dilatation of the left ventricle after
LAD ligation. In the mESC group, however, restoration of
the left ventricular wall mass and reduction of left ventricular
dilatation were seen. Colocalization of GFP with troponin
and a-sarcomeric actin in isolated cells demonstrated poten-
tial differentiation of the mESCs into cardiomyocytes, as
shown in Figure 5 (E–H). Colocalization of GFP with
connexin 43 suggests the formation of gap junctions, as
represented in Figure 5, I.
Discussion
Cardiomyocyte death or dysfunction after an AMI results in
pathologic remodeling of the left ventricle, with the eventual
sequela of heart failure. Despite recent reports of the regener-
ative potential of cell-based therapies in the injured myocar-
dium, a definitive mechanism of this enhanced myocardial
function has not been elucidated. In this study, we have pro-
vided independent support for in vivo MRI data by PV loop
examination and have established the fundamental biologic
importance of cell survival, cell differentiation, and paracrine
effects as potential mechanisms of mESCs underlying myo-
cardial restoration. The investigation focused on the immedi-
ate effects of cellular transplants after AMI because teratoma
formation would likely have interfered with reliable measure-1034 The Journal of Thoracic and Cardiovascular Surgery c Oments during longer follow-up,15 as the greatly increased
mESC BLI signal on POD 14 confirmed. Our data demon-
strated significantly improved LVEF measured by in vivo
MRI, themost commonly used clinical end point. This finding
was confirmed byEes andEMaxvaluesmeasured byPV loop,
indicating improved systolic and diastolic functions as early
as 1 week after mESC treatment. The improvement in dia-
stolic function in themESCgroup can be attributed to the aug-
mentation of the infarct region’s elasticity and recovery in the
overall EMax. Moreover, we found a correlation between left
ventricular volume measurements by MRI and PV loop.
These findings challenge the current notion that myocar-
dial function is improved irrespective of cell type.16,17 The
preservation of cardiac performance after cellular transplant
cannot be attributed merely to the physical scaffolding effect
but also must arise from the biologic properties of the trans-
planted cells. During myocardial ischemia, the ischemic
region develops diastolic and subsequent systolic abnormal-
ity.18 Studies have confirmed the Frank–Starling relationship,
in which contractile function is preserved with reduction in
ventricular volume.19 In fact, our PV loop results indicate a re-
duction in ventricular volume in themESC group. This reduc-
tion involves complex yet fundamental biologic processes.
Figure 4. Relative quantitation of tumor necrosis factor a (TNF)
and vascular endothelial growth factor A (VEGF) expressions. Rel-
ative quantitation of messenger RNA expression on postoperative
day 7, normalized as percentage of expression in normal, sham-
operated hearts. Significant upregulation is noticeable in mouse
embryonic stem cell (mESC) group. Asterisk indicates P < .01 by
analysis of variance versus mouse embryonic fibroblast (mEF)
and normal saline–treated (NS) groups. Double asterisk indicates
P < .01 by analysis of variance versus all other groups.ctober 2008
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PFigure 5. Histopathologic examination of antiremodeling effect and cardiomyocyte differentiation after transplant of
mouse embryonic stem cells on postoperative day 7. A–D, Representative cross-sectional images of hematoxylin
and eosin–stained normal heart (A); left anterior descending coronary artery ligation control (NS, B), demonstrating
thinning and dilatation of ventricular wall; C, heart treated with mouse embryonic fibroblasts (mEF); and heart
treated with mouse embryonic stem cells (mESC), demonstrating restoration of left ventricular wall mass. E, Con-
focal microscopy showing mouse embryonic stem cells (mESC) staining positive for green fluorescent protein
(GFP). Confocal microscopy showing same cells as in D expressing troponin; 7-mm clustered round structures prob-
ably represent nonspecifically stained red blood cells. G, Overlay of D and E, showing colocalization of green fluo-
rescent protein (GFP) with troponin, suggestive of mouse embryonic stem cell–derived cardiomyocyte. Note
nonspecifically colored blood cells located inside green fluorescent protein–stained blood vessel (white arrow),
suggesting mouse embryonic stem cell–derived neovasculogenesis. H, Image showing colocalization of green fluo-
rescent protein (GFP)–positive mouse embryonic stem cells (mESC) with a-sarcomeric actin. I, Image showing
colocalization of green fluorescent protein (GFP) with connexin 43 (white arrow).The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 1035
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CSPFirst, the prolonged survival kinetics of mESCs can offer
a longer lasting scaffolding effect, which may help to explain
both the reduction in pathologic remodeling and the sustained
restoration. More importantly, however, the persistence of vi-
able mESCs generates biologically active stimuli to salvage
the injured myocytes. Thus this enhanced survival of mESCs
enables a second potential mechanistic explanation for in vivo
MRI findings of myocardial restoration, a paracrine effect.
The results of ex vivo TM-PCR demonstrate that the potential
antiapoptotic cytokine TNF-a was significantly upregulated
in the mESC group. TNF-a has been shown to have negative
inotropic effects, to induce resistance to hypoxic stress in
cardiomyocytes, and to play a role in the recruitment of
stem cells.20-23 It must be stated, however, that the increased
TNF-a expression could also be attributable to a greater
mass effect of mESCs, with a subsequent greater endogenous
inflammatory reaction, a greater mESC-induced monocyte
influx, or teratoma formation leading to endogenous TNF-
a production. In addition, the observed upregulation of
VEGF-A in this study may have promoted angiogenesis to
attenuate the ischemic insult and allow recovery of the injured
cardiomyocytes. Finally, nonsignificant trends towards
downregulation of MMP-1 and procollagen 2a1 have also
been detected, which may contribute to decreased cardiac
matrix remodeling in failing hearts.24 Surprisingly, we did
not observe upregulation of MMP-2 and MMP-9. This may
have been because of the absence in the SCIDmice of T cells,
on which MMP-2 and MMP-9 expressions have been shown
to depend.25 Taken together, these TM-PCR results suggest
that multiple mechanisms underlie the restoration by mESC
treatment.
The pluripotency of mESCs may lead to regeneration of
cardiac tissue after cardiomyogenic differentiation.26 To con-
tract synchronously with host cardiomyocytes, newly formed
mESC-derived cardiomyocytesmust undergo electromechan-
ical coupling through the formation of gap junctions in vivo
with the host myocardium.26,27 This study provides possible
evidence that donor mESCs are capable of engrafting within
the host myocardium and differentiating into cardiomyocytes.
Although these findings are encouraging, it must be noted that
this was a low-frequency event, making it less likely that the
observed functional improvement can be attributed to robust
cardiac regeneration by mESC-derived cardiomyocytes.
There are several limitations of this study. First, to inves-
tigate the acute effect of cell survival, we chose to compare
fast-growing, undifferentiated mESCs with less active
mEFs. This gave us the opportunity to study the relationship
between cardiac function and cell survival in the relatively
short period of 1 week. It must be stated, however, that even-
tual teratoma formation, as suggested by our BLI findings on
POD 14 and consistent with the literature,13,15,28 would likely
hamper long-term restoration of cardiac function. Second,
this study does not provide insight into acute postoperative
infarct size, which may have been dependent on cell type.1036 The Journal of Thoracic and Cardiovascular Surgery c OcAll operations, however, were conducted by the same expe-
rienced microsurgeon who was blinded to the study. More-
over, after 1 week, all operated groups had a significantly
compromised LVEF on MRI, leading to the assumption
that initial infarct size was comparable among all study
groups. Third, we focused on validating the most important
MRI data, namely left ventricular end-diastolic and left ven-
tricular end-systolic volumes. Wall thickness, which may
have correlated with cell survival, was not measured because
we did not anticipate regenerative changes in the immediate
period after AMI. Other studies are currently underway to ad-
dress the regenerative changes by measuring wall thickness.
In conclusion, this is the first study to provide a fundamen-
tal functional and biologic evaluation of in vivo MRI in
mESC therapy. This study has shown that mESCs are supe-
rior to mEFs in restoring cardiac function in the immediate
post-AMI period. A fundamental notion that the cells must
at the very least survive to restore the myocardium is con-
firmed by the finding that the enhanced survival of mESCs
is among the key factors in myocardial restoration. Improved
survival of transplanted cells may offer not only a physical
scaffolding mechanism but, more importantly, biologic sup-
port by generating sustained paracrine effects after injury.
We have also observed that mESCs retain the ability to differ-
entiate into cardiomyocytes, albeit at low frequency. Unfor-
tunately, although the pluripotency and robust proliferation
are among the major advantages of embryonic stem cells,
these characteristics also contribute to teratoma forma-
tion,13,15 which for the present prevents clinical translation.
Further research regarding directed differentiation of mESCs
into cardiomyocytes may lead to a safe regenerative therapy
for myocardial disease in the future.
We greatly appreciate the assistance with immunohistology from
Ms Pauline Chu and the help with PCR from Ms Sally Zhang and
Mr Anant Patel.
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Cardiopulmonary Support and Physiology Hendry II et alTABLE E1. Steady-state hemodynamic measurements by magnetic resonance imaging and pressure–volume loop
Infarct treatment groups
Normal (no infarct) mESC mEF Normal saline
Magnetic resonance imaging
LV ejection fraction (%) 60.9 6 1.4 40.2 6 2.0 29.4 6 1.5 26.4 6 1.8
LV end-diastolic volume (mL) 4.23 6 0.5 4.53 6 0.6 5.74 6 0.6 8.32 6 0.7
LV end-systolic volume (mL) 1.63 6 0.2 2.67 6 0.2 4.09 6 0.3 6.14 6 0.5
Pressure–volume loop
Heart rate (beats/min) 277.25 6 10.60 302.75 6 26.93 319.25 6 16.45 260.00 6 22.51
End-systolic volume (mL) 26.72 6 0.49 21.65 6 4.82 40.56 6 8.67 45.82 6 8.89
End-diastolic volume (mL) 29.29 6 0.47 24.00 6 5.56 43.15 6 9.21 49.40 6 9.67
End-systolic pressure (mm Hg) 83.86 6 9.17* 85.92 6 5.91* 71.40 6 6.55 49.84 6 5.35
End-diastolic pressure (mm Hg) 5.15 6 1.21 19.14 6 7.01 6.50 6 0.54 8.21 6 1.64
Arterial elastance (mm Hg/mL) 29.34 6 9.50 37.50 6 11.56 22.04 6 3.88 10.62 6 3.35
Maximum differential of pressure (mm Hg/s) 4100.50 6 412.10 3867.50 6 751.61 3108.75 6 293.20 2157.00 6 358.83
Minimum differential of pressure (mm Hg/s) 22993.25 6 138.66* 22779.75 6 144.06* 22397.75 6 107.80 21578.50 6 304.29
Tau (Weiss) 15.01 6 1.32 21.38 6 4.32 15.13 6 1.16 12.75 6 3.89
Maximal power (mW) 0.79 6 0.10 0.78 6 0.07 1.15 6 0.45 0.84 6 0.27
Preload-adjusted maximal
power (mW/mL2)
9.21 6 1.19 18.88 6 6.13* 5.87 6 0.76 3.69 6 1.25
Values are mean 6 SE. mESC, Mouse embryonic stem cell treatment; mEF, mouse embryonic fibroblast treatment; LV, left ventricle. *P , .05 versus normal
saline group by analysis of variance.1037.e1 The Journal of Thoracic and Cardiovascular Surgery c October 2008
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